DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma by DocMorris, and TeleClinic brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.…
DocMorris Aktie News: DocMorris wird am Freitagmittag ausgebremst
DocMorris (SWX: DOCM) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Pharmaceutical Retailers industry, part of the Healthcare sector, and reports about 1,097 employees.
The shares were at 18.53 CHF on 20 November 2026, up 265.8% over 52 weeks. Its 52-week range is 3.922 CHF to 19.50 CHF: the price is 5.0% below the high and 372.5% above the low.
Its market capitalisation is 944.69M CHF.
DocMorris reports return on equity of -32.9%, an operating margin of -7.3% and revenue up 14.9% year over year.
Its debt exceeds its cash by 166.48M CHF, a debt-to-equity ratio of 0.71. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 17.16 CHF is 7.4% below the current price. The next earnings report is expected on 18 March 2027.